Your browser doesn't support javascript.
loading
Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network.
Hofste op Bruinink, Davine; Oliva, Stefania; Rihova, Lucie; Schmitz, Alexander; Gilestro, Milena; Te Marvelde, Jeroen; Kralova, Romana; Høholt, Helle; Broijl, Annemiek; Johnsen, Hans Erik; Hajek, Roman; Boccadoro, Mario; Sonneveld, Pieter; Omedè, Paola; Van der Velden, Vincent H J.
Afiliação
  • Hofste op Bruinink D; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands . d.hofsteopbruinink@erasmusmc.nl.
  • Oliva S; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
  • Rihova L; Department of Hematology, University Hospital Brno, Brno, Czech Republic.
  • Schmitz A; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
  • Gilestro M; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
  • Te Marvelde J; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Kralova R; Department of Hematology, University Hospital Brno, Brno, Czech Republic.
  • Høholt H; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
  • Broijl A; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Johnsen HE; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
  • Hajek R; Department of Hemato-oncology, University Hospital Ostrava and Faculty of Medicine, Ostrava University, Ostrava, Czech Republic.
  • Boccadoro M; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
  • Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Omedè P; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
  • Van der Velden VHJ; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands . v.h.j.vandervelden@erasmusmc.nl.
Haematologica ; 106(5): 1496-1499, 2020 10 05.
Article em En | MEDLINE | ID: mdl-33054135
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda